News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Giannis Mountzios: DeLLphi-304 Trial on Tarlatamab vs SoC Chemotherapy in Patients with Pre-Treated SCLC at ASCO25
Giannis Mountzios/X
May 19, 2025, 10:50

Giannis Mountzios: DeLLphi-304 Trial on Tarlatamab vs SoC Chemotherapy in Patients with Pre-Treated SCLC at ASCO25

Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on LinkedIn:

“Following the presentation of the landmark DeLLphi-304 trial on Tarlatamab vs SoC Chemotherapy in pts with pre-treated SCLC in ASCO25, join Dr Jacob Sands and me on June 17th in a hands-on, comprehensive read-out discussion on DLL-3 T-cell engagers and SCLC hosted by only Peters Solange.

Link to Registration.”

Giannis Mountzios announced his upcoming participation in a post-ASCO25 discussion on the DeLLphi-304 trial and the role of DLL3 T-cell engagers in small cell lung cancer. The session will take place on June 17 and be hosted by Peters Solange, with Dr. Jacob Sands also contributing.

Giannis Mountzios: DeLLphi-304 Trial on Tarlatamab vs SoC Chemotherapy in Patients with Pre-Treated SCLC at ASCO25

More posts featuring Giannis Mountzios.

ASCO25 cancer DeLLphi-304 Tria DLL-3 T-cell fight against cancer Giannis Mountzios Global fight against cancer Henry Dunant Hospital Center Jacob Sands OncoDaily Oncology Peters Solange SCLC SoC Chemotherapy Tarlatamab
Special Coverage
Blog
May 19, 2025, 10:50
Giannis Mountzios: DeLLphi-304 Trial on Tarlatamab vs SoC Chemotherapy in Patients with Pre-Treated SCLC at ASCO25
Blog
May 19, 2025, 10:41
Mohamed Janabi Nominated as Next WHO Africa Regional Director - World Health Organization African Region
Blog
May 19, 2025, 10:26
Hadi Mohamad Abu Rasheed: A Shared Mission for Hematology Care in the GCC
Blog
May 19, 2025, 10:14
Karina Herrera Schoene: The CAR-T Cell Immersion at the University of Miami
Blog
May 19, 2025, 10:12
Giannis Mountzios: Join Upcoming Discussion on DLL3 T-Cell Engagers in SCLC
Blog
May 19, 2025, 10:11
Wafaa M Rashed: EMBL-EBI’s Ensembl Team Provides Training in Genome Interpretation Tools for African Genomics Researchers
Blog
May 19, 2025, 10:03
Chris Poulios: The European Society of Pathology Newsletter-Spring 2025, Has Just Been Sent to ESP Members
Blog
May 19, 2025, 10:02
Drew Moghanaki: VA’s Leadership in Lung Cancer Screening
Blog
May 19, 2025, 10:00
Society of Surgical Oncology - Applications are Open for the IASO Observership
Blog
May 19, 2025, 09:56
Herbert Loong: My Medical Oncology Specialist Exitexamination Project Just Received 100 Citations
Science
May 19, 2025, 09:53
Rahul Banerjee: Safety and Activity of Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
Blog
May 19, 2025, 09:45
Join the ASGO Webinar on HPV-related Neoplasia